摘要
Abstract
Objective To evaluate the efficacy of entecavir treatment up to 96 weeks for patients with chronic hepatitis B (CHB).Methods The study recruited 62 CHB patients who were admitted to or hospitalized at the Taixing People′s Hospital from July 201 1 to July 2014. The patients were treated with entecavir (0.5 mg/d)for 96 weeks of antiviral therapy.All the patients were divided into HBeAg-positive (n=43)and HBeAg-negative groups (n=19).The HBV DNA load was higher than 106 copies/ml in 38 patients and lower than 106 cop-ies/ml in 24 patients.The efficacy of entecavir in the two groups was compared at 24,48,and 96 weeks of treatment.Between-group com-parison of categorical data was performed byχ2 test.Results At 24,48,and 96 weeks of treatment,the HBeAg-positive group had a sig-nificantly lower HBV DNA clearance rate than the HBeAg -negative group (34.88% vs 78.95%,P=0.003;65.12% vs 89.47%, P=0.047;74.42% vs 100%,P=0.038);there was no significant difference in alanine aminotransferase (ALT)normalization rate be-tween the two groups (P=0.102,0.779,and 0.638).Patients with a HBV DNA load of >106 copies/ml had a significantly lower HBV DNA clearance rate than those with a HBV DNA load of <106 copies/ml at 24,48,and 96 weeks of treatment (34.21% vs 70.83%, P=0.005;57.89% vs 95.83%,P=0.001;76.32%vs 95.83%,P=0.002);there was no significant difference in ALT normalization rate between the two groups (P=0.940,0.150,and 0.280).Conclusion Entecavir has a high antiviral activity in the treatment of CHB, which can suppress HBV replication and concurrently improve liver function.关键词
肝炎,乙型,慢性/恩替卡韦/治疗结果Key words
hepatitis B,chronic/entecavir/treatment outcome分类
医药卫生
